On August 11, Intuitive Surgical rose 3.03% in regular trading, trading at approximately $390.05/share, with turnover of $683 million. The gain was driven by broad strength across the medical device sector combined with an oversold technical rebound.

On the sector front, medical equipment names rallied broadly, with DexCom up 3.56%, Boston Scientific up 2.73%, Medtronic up 1.99%, Stryker up 1.02%, and Abbott Laboratories up 0.87%, providing a supportive backdrop for the rebound. Intuitive Surgical had previously plunged over 11% following its Q2 earnings report in mid-July, despite adjusted EPS of $2.80 beating the $2.50 consensus by 12% and revenue of $2.89 billion rising 18% year-over-year. The selloff was triggered by management maintaining its full-year da Vinci procedure growth outlook of 13.5%-15.5% without an upward revision, disappointing investors expecting raised guidance.

Since the earnings report, multiple firms have cut price targets, with the consensus mean falling to approximately $479. HSBC downgraded the stock to Hold with a $391 target, while UBS upgraded to Buy with a $500 target. BMO Capital highlighted the stock trades at a roughly 31% discount to its three-year historical P/E, calling it a historically attractive entry point amid capital rotation toward AI sectors rather than fundamental deterioration.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)